Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.18 -6.49%

-$0.30 today

Market cap
$108.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.28M

Average 0.21M

NERV Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Minerva Neurosciences, Inc.NASDAQ: NERV

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 161575.2% from a year ago

Cash & equivalents stood at $24.65B at the end of Q2 FY2026, up 161575.2% from a year earlier and up 75151.1% from the prior quarter. Over 3 fiscal years it compounded at +31.6% a year.

Context

  • Cash & equivalents amounted to 25.9% of total assets at the end of Q2 FY2026, down 24.2 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +161575.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$24.65B+75151.1% QoQ
Last fiscal yearDec 2025
$82.3M+285.3% YoY
Year agoJun 2025
$15.25M+161575.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+161575.2%——
1 year+285.3%——
3-year CAGR+31.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
82.3M USD
Year-over-year change
+285.3%
4-year CAGR
+7.9%

Cash & Equivalents vs competitors

How NERV compares with its peers on the latest reported figures

  • NERV's Jun 2026 cash & equivalents of $24.65B is the highest of the 4 companies compared; the peer median is $7.08M.
  • Its year-over-year change of +161575.2% is the highest of 4, against a peer median of +179.4%.
  • Cash & equivalents amounts to 25.9% of total assets for NERV, versus a peer median of 75.8%.
NERV Competitors Peer median
Cash & Equivalents for NERV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NERVMinerva Neurosciences, Inc.Jun 2026$24.65B +161575.2%+31.6%25.9%
RLYBRallybio CorporationMar 2026$41.3M +179.4%-18.0%75.8%
NRXSNeurAxis, Inc.Mar 2026$7.08M +253.0%+169.5%80.9%
ENLVEnlivex Therapeutics Ltd.Dec 2025$2.01M -39.2%-65.7%0.1%
Peer median (excluding NERV) $7.08M+179.4%-18.0%75.8%

Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.76M36.09M40.91M21.36M82.3M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets100K4.07M1.09M906.9K798K
Total Current Assets62.2M40.16M42M22.27M83.1M
Property, Plant & Equipment (Net)51.08K16.33K10.88K5.44K0
Goodwill14.87M14.87M14.87M14.87M14.87M
Intangible Assets042.57K17.03K00
Long-term Investments00000
Tax Assets00000
Other Non-current Assets(1)0000
Total Non-current Assets14.92M14.93M14.9M14.87M14.87M
Total Assets77.12M55.09M56.9M37.14M97.97M
Account Payables1.85M969.67K1.81M1.61M639K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities014.83K590.77K363.18K(473)
Total Current Liabilities2.82M1.38M3.34M2.84M2.29M
Long-term Debt000064.96M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities66.33M73.73M82.02M60M171.46M
Total Non-current Liabilities66.33M73.73M82.02M60M236.43M
Total Liabilities69.15M75.11M85.36M62.84M238.72M
Common Stock5345346996994.33K
Retained Earnings(334.7M)(366.81M)(396.82M)(395.38M)(688.8M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity7.98M(20.02M)(28.46M)(25.69M)(140.75M)
Total Debt000064.96M
Net Debt(60.76M)(36.09M)(40.91M)(21.36M)(17.34M)

Minerva Neurosciences, Inc.

NASDAQ:NERV

Intrinsic Alpha fair value

Locked

Current Price

$2.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.